AKIGAI_001: Bruk av kjente EGFR-hemmere mot nevropatiske smerter (fase 1)

Offentlig prosjektsammendrag

AKIGAI is on a mission to drastically increase access to effective and lasting pain relief for all patients with neuropathic pain (NeuP). Drug repurposing can significantly reduce timelines and costs compared with de novo drug development. AKIGAI’s founders have published and patented that Epidermal Growth Factor Receptor inhibitors, a type of anti-cancer drug that has been used in oncology for over 20 years, work exceptionally well against NeuP. The primary objective of the project is to prove safety in preclinical activities for NeuP and ensure readiness for a phase II/III clinical trial. The repurposed drug will be developed based on well-documented active ingredients but with different dosages and a new improved formulation that is tailored to the new NeuP indications.